Dual antiplatelet therapy with aspirin and a P2Y 12 inhibitor is the treatment of choice for the prevention of atherothrombotic events in
Switching from ticagrelor to clopidogrel in patients with ST‐segment elevation myocardial infarction undergoing successful percutaneous coronary
One prior study has shown that treatment with a direct-acting, reversible P2Y 12 inhibitor, elinogrel, can overcome clopidogrel nonresponsiveness
4%, and switching from ticagrelor to clopidogrel resulted in an absolute IPA
Since the study duration was from January 2014 to March 2018, the current rates and reasons for switching between ticagrelor and clopidogrel may be different now
Ticagrelor 180 mg given 1 hour prior to discontinuation of the cangrelor infusion, followed by 90 mg twice daily
7,8 The availability of different oral P2Y 12 inhibitors has enabled physicians to con-template switching among therapies because of specific clinical scenarios
When combined with an anticoagulant, clopidogrel is the recommended antiplatelet agent for most patients
com
Applies to: Plavix (clopidogrel) and Brilinta (ticagrelor) Using ticagrelor together with clopidogrel may increase the risk of bleeding
0%, p<0
This editorial refers to ‘A head-to-head pharmacodynamic comparison of prasugrel vs
Based on the results of this major clinical study, the FDA determined that BRILINTA 90 mg is superior to Plavix for at least the first 12 months following ACS
Patients can be switched from clopidogrel to ticagrelor without interrupting the antiplatelet effect
It is also used to reduce the risk of blood clots in patients It prevents blood clots by binding to the P2Y12 receptor on platelets, preventing adenosine diphosphate (ADP) from activating platelets
1
61% of reviewers reported a positive effect, while 24% reported a negative effect
Therefore, some institutions and providers switch patients from ticagrelor or prasugrel to clopidogrel in an effort to lower bleeding risk, stem costs, or otherwise ensure that patients can safely adhere to long-term P2Y12 inhibitor therapy